Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Capital Raise

Arcus Biosciences Shares Rise 5% in 12 Days Since Capital Raise

Arcus Biosciences Completes $287.5 Million Public Offering of Common Stock

+5.99% in 12 days $18.52 when we broke this story → $19.63 peak on 4 Nov 2026

Arcus Biosciences has successfully closed an underwritten public offering of common stock, generating net proceeds of approximately $269.7 million. The transaction included the full exercise of the underwriters' over-allotment option, significantly bolstering the company's cash position for its clinical development pipeline.

Dna, windows wallpaper, 3d, biology. Stock photo illustrating Arcus Biosciences' capital raise story.
Arcus Biosciences, Inc. · Healthcare · Photo: Mahmoud-Ahmed / Pixabay
Key numbers
Deal value$288M
Share of market cap12.2%

Key highlights

  • Issuance of 16,428,572 total shares of common stock at a public price of $17.50 per share
  • Exercise in full of the underwriters' option to purchase an additional 2,142,857 shares
  • Net proceeds of $269.7 million realized after deducting underwriting discounts and commissions
  • Transaction led by Jefferies LLC, Leerink Partners LLC, and TD Securities (USA) LLC
  • Capital infusion occurs as the company maintains a market capitalization of $2.36 billion

Details of the Offering

Arcus Biosciences, Inc. (NYSE: RCUS) finalized an underwritten public offering of 14,285,715 shares of common stock at a price of $17.50 per share. Concurrently, the underwriters exercised their 30-day option to purchase an additional 2,142,857 shares in full. The closing of the offering on October 23, 2026, resulted in the issuance of 16,428,572 shares. After accounting for underwriting discounts and estimated offering expenses, the company received approximately $269.7 million in net proceeds. Jefferies LLC, Leerink Partners LLC, and TD Securities (USA) LLC served as the representatives of the several underwriters for the transaction.

Strategic Rationale

The capital raise follows a series of public offerings by Arcus, including previous transactions in February 2025 and October 2025. By securing nearly $270 million in fresh capital, the company addresses the high operational costs associated with its clinical-stage oncology programs. The transaction occurred during a period where the stock's Relative Strength Index (RSI) reached 27.5, indicating technical oversold conditions. This proactive funding strategy allows the company to maintain its development momentum without immediate reliance on milestone-dependent payments or new partnership agreements, providing a buffer against market volatility in the biotechnology sector.

Financial Context

  • The company previously guided that existing cash reserves would fund operations until at least the second half of 2028
  • Full-year 2026 GAAP revenue guidance was established between $45 million and $55 million
  • Quarterly revenue of $41.0 million is primarily derived from strategic collaborations rather than product sales
  • The company reported annual revenue of $247.0 million for the prior fiscal year
  • Net proceeds from this offering will supplement the existing cash and marketable securities balance
Arcus Biosciences, Inc. share price · last month
Line chart of Arcus Biosciences, Inc.'s share price over the last month, from $22.14 on 19 Oct → $16.86 on 16 Nov; our story on 23 Oct at $18.52.

Down 9.0% since our story on 23 Oct: $18.52 when we broke it → $16.86 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$22.14
20 Oct$23.75
21 Oct$19.10
22 Oct$19.36
23 Oct$18.54
26 Oct$17.76
27 Oct$18.14
28 Oct$18.39
29 Oct$18.61
30 Oct$18.19
2 Nov$17.85
3 Nov$18.91
4 Nov$19.31
5 Nov$17.69
6 Nov$18.28
9 Nov$18.95
10 Nov$18.67
11 Nov$18.80
12 Nov$17.77
13 Nov$17.43
16 Nov$16.86

Business Overview

Arcus Biosciences is a California-based clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. The company’s research and development efforts target various biological pathways, including TIGIT, adenosine, and HIF-2a. As a clinical entity, Arcus does not currently have approved commercial products and generates revenue primarily through its collaboration agreement with Gilead Sciences. The company’s pipeline includes several late-stage candidates aimed at treating solid tumors. This latest capital injection supports the continued advancement of these candidates through complex clinical trials and regulatory filing preparations.

Earlier announcements by Arcus Biosciences, Inc.
DateAnnouncementAmount
21 Oct 2026Underwritten public offering of common stockSource: stockanalysis.com$250.0 Million
30 Oct 2025Underwritten public offering of common stockSource: investors.arcusbio.com$250.0 Million
18 Feb 2025Underwritten public offering of common stockSource: investors.arcusbio.com$150.0 Million
Arcus Biosciences, Inc. · financial snapshot
Share price$18.52
Market cap$2.4B
Revenue (annual)$247M
1-month price change-29.82%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Arcus Biosciences, Inc. announcing the closing of a $287.5 million public offering of common stock.

Read the filing ↗
All Arcus Biosciences, Inc. filings and newsView all →

Track Arcus Biosciences, Inc. live

Get the next Arcus Biosciences, Inc. SEC filing seconds after it lands.

More from Arcus Biosciences, Inc.

All →

More in Capital Raise

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.